Cancer
Malignant Esophageal Neoplasm
CI-CAN-00001127Explore in graph →
Top-level518 active trials6 approved drugs12 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001127Explore in graph →
Clinical trials
1,926 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06335966 | BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy(BEST-RPP) | active not recruiting | — | 110 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07469241 | Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.(FUTURE-3) | not yet recruiting | Phase 2 | 50 | Fudan UniversityOTHER |
| 0 |
| Mar 13, 2026 |
| clinicaltrials |
| NCT06349642 | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform(ELEPHAS-04) | recruiting | — | 324 | Mayo ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07464470 | Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers(GENCONCOR-2) | recruiting | — | 30 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT00587314 | The Effect of Ablation Therapy on Barrett's Esophagus(ablation IN BE) | enrolling by invitation | — | 600 | Mayo ClinicOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07104214 | Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy | recruiting | — | 5,000 | Zhejiang UniversityOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07175155 | Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients | recruiting | N/A | 410 | Zhejiang UniversityOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07457528 | Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC | recruiting | Phase 2 | 46 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07354295 | Integrating Multimodal AI to Predict Treatment Response and Refine Risk Stratification in Esophageal Cancer （Radiogenomics-Esophagus） | recruiting | — | 1,500 | Shu PengOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07455019 | A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer | recruiting | Phase 2 | 28 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT00899626 | Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients | recruiting | — | 5,000 | Vanderbilt University Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04075305 | The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study(MOMENTUM) | recruiting | — | 8,000 | UMC UtrechtOTHER | 9 | Mar 5, 2026 | clinicaltrials |
| NCT04900818 | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 330 | I-Mab Biopharma US LimitedINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT07448493 | Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer(GASTROBRAIN) | active not recruiting | — | 230 | Blokhin's Russian Cancer Research CenterOTHER | 2 | Mar 4, 2026 | clinicaltrials |
| NCT07446335 | A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 578 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03403465 | Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers | active not recruiting | Phase 2 | 90 | Duke UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06356311 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)(TroFuse-015) | active not recruiting | Phase 3 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Feb 27, 2026 | clinicaltrials |
| NCT06452602 | Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC. | recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07039162 | Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 45 | Ming-Yu LienOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07435454 | Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 22 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07437898 | Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study | recruiting | Phase 2 | 42 | The Affiliated Hospital of Putian UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04430738 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | active not recruiting | Phase 2 | 40 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT05438420 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Qurient Co., Ltd.INDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT06523374 | A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer(Endeavor-1) | recruiting | N/A | 50 | University Hospital, AntwerpOTHER | 6 | Feb 24, 2026 | clinicaltrials |
| NCT03174275 | Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 2 | 39 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04258813 | Onco-primary Care Networking to Support TEAM-based Care(ONE TEAM) | active not recruiting | N/A | 313 | Duke UniversityOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04354064 | Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors | recruiting | — | 100 | Washington University School of MedicineOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04868877 | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | active not recruiting | Phase 1 / Phase 2 | 194 | Merus B.V.INDUSTRY | 9 | Feb 19, 2026 | clinicaltrials |
| NCT06346080 | Molecular Analysis for Gastro-Esophageal Cancer: Multicenter Discrete Choice Experiment(MAGECmultiDiCE) | recruiting | N/A | 2,200 | KU LeuvenOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06346054 | Molecular Assessment for Gastro-Esophageal Cancer(MAGEC) | recruiting | N/A | 1,000 | KU LeuvenOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07406815 | The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy | not yet recruiting | Phase 3 | 144 | Fujian Medical University Union HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06623396 | A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer | recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07403435 | Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC | not yet recruiting | Phase 2 | 22 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05775939 | PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial | recruiting | N/A | 20 | Thomas Jefferson UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03740256 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors(VISTA) | recruiting | Phase 1 | 45 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07390838 | A Study of SH009 Injection in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 150 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07385664 | Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC(FAIR) | not yet recruiting | Phase 2 | 66 | Ji YonglingOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07382635 | Clinical Trial Protocol for Evaluating the Efficacy and Safety of Thoracoabdominal Endoscopic Surgery System in Remote Laparoscopic Surgery for Urology, General Surgery, Gynecology and Thoracic Surgery | not yet recruiting | — | 98 | Cornerstone RoboticsINDUSTRY | 0 | Feb 3, 2026 | clinicaltrials |
| NCT07385001 | A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC | recruiting | Phase 1 / Phase 2 | 45 | Tang-Du HospitalOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05621707 | Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)(RICE) | active not recruiting | Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04871412 | The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III(POISE) | recruiting | Phase 3 | 20 | Ottawa Hospital Research InstituteOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06952621 | Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma(TD-NEOE3V3) | not yet recruiting | Phase 3 | 390 | Tang-Du HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07376876 | Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy | not yet recruiting | Phase 2 | 73 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04290806 | Registry Platform Gastric/Esophageal Cancer (SAPHIR)(SAPHIR) | recruiting | — | 1,900 | iOMEDICO AGINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07371247 | Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy | enrolling by invitation | Early Phase 1 | 65 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT03961945 | Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma | recruiting | N/A | 1,550 | Mayo ClinicOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT05978193 | Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma(SCR-ESCC-01) | recruiting | Phase 2 | 100 | Shanghai Chest HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07359417 | MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma(ESCALATE) | recruiting | Phase 1 | 30 | UMC UtrechtOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03539822 | Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies(CAMILLA) | recruiting | Phase 1 / Phase 2 | 117 | Anwaar SaeedOTHER | 1 | Jan 21, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 17, 2026source: clinicaltrials